Get Adobe Flash player

CORRECTION OF THE NON-ALCOHOLIC STEATOHEPATITIS MANIFESTATIONS IN THE PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY

Authors: Rudenko T.

Pages: 191-195

 

Abstract

    The article proves the effectiveness of the ursodeoxycholic acid drug application for the non-alcoholic steatohepatitis treatment in the patients with hypertension and obesity. Application of the ursodeoxycholic acid drug accelerates normalization of clinical manifestations, normalization of biochemical parameters of liver function and lipid metabolism, reduces sonographic phenomenon of the fatty liver infiltration. The positive clinical effects and positive dynamics of biochemical and sonographic indicators confirm enhancement of metabolism in the liver cells in the majority of patients. These factors may recommend the ursodeoxycholic acid application for treatment and prevention.

Key words: non-alcoholic steatohepatitis, hypertension, obesity, ursodeoxycholic acid.

             * This email address is being protected from spambots. You need JavaScript enabled to view it.

 

The full text

To view the full text

 

References

1. Сіренко Ю.М. Гіпертонічна хвороба: довідкове видання // Юрій Миколайович Сіренко. – К.: Здоров`я, 2009. – 240 с. 
2. Bellentani S. Epidemiology and risk factors for fatty liver / S. Bellentani, C. TinBelli // Dordrecht: Kluwer Academic Publisher, 2001. – 89 p.
3. Essential hypertension and chronic viral hepatitis / G. Parrilli, F. Manguso, L. Orsini [et al.] // Dig Liver Dis. – 2007. – Vol. 39 (5). – P. 466–72. 
4. Бутрова С.А. Современная фармакотерапия ожирения / С.А. Бутрова // Consilium Medicum. – 2004. - Том 6, № 9. – С. 669-674. 
5. Бабак О.Я. Проблема фиброгенеза неалкогольной жировой болезни печени / О.Я. Бабак // Сучасна гастроентерологія. – 2007. - № 4 (36). – С. 4-10.
6. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease / F. Angelico, M. Del Ben, R. Conti [et al.] // J Clin Endocrinol Metab. – 2005. – Vol. 90. – P. 1578–1582.
7. Abdelmalek M.F. Nonalcoholic fatty liver disease as a complication of insulin resistance / M.F. Abdelmalek, A.M. Diehl // Med Clin North Am. – 2007. – Vol. 91. – P. 1125–1149.
8. Pharmacological treatment of non–alcoholic steatohepatitis: the current evidence / M.C. Diakou, E.N. Liberopoulos, D.P. Mikhailidis [et al.] // Scand J Gastroenterol. - 2007. – Vol. 42. – P. 139–147.
9. Костюкевич О.И. Артериальная гипертензия и болезни печени: в поисках компромисса / О.И. Костюкевич // Русский мелицинский журнал. – 2011. - № 5. – С. 338-342.
10. Fallo F. Non–alcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients / F. Fallo, A. Dalla Pozza, N. Sonino // J Hypertens. – 2008. - Vol. 26 (11). – P. 2191–2197.
11. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy / G. Targher, L. Bertolini, G. Zoppini [et al.] // Diabet Med. – 2005. – Vol. 22. – P. 999–1004. 
12. Кузнецова Е.Л. Новые данные о молекулярных механизмах гепатобилиарного транспорта / Е.Л. Кузнецова, Е.Н. Широкова, В.Т. Ивашкин // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. – 2006. - № 6. - С. 8-11.
13. Wanless I.R. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis / I.R. Wanless, K. Shiota // Semin. Liver Dis. – 2004. - № 24. – P. 99-106.
14. Лазебник Л.Б. Метаболический синдром с позиции гастроэнтеролога / Л.Б. Лазебник, Л.А. Звенигородская, Е.Г. Егорова // Русский медицинский журнал. – 2005. - Т. 13, № 26.
15. Довженко Л.И. Пациент с ишемической болезнью сердца и хроническим стеатогепатитом: как проводить гиполипидемическую терапию / Л.И. Довженко // Український медичний часопис. – 2007. – № 1. – С. 1-4.
16. Фадеенко Г.Д. Стеатогепатит. Биохимические маркеры и проблемы диагностики / Г.Д. Фадеенко, Н.В. Кравченко // Сучасна гастроентерологія. – 2006. - №1 (28). – С. 8-14.
17. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity / N. Chalasani, H. Aljadhey, J. Kesterson [et al.] // Gastroenterology. – 2004. – Vol. 126. – P. 1287–1292. 
18. Vuppalanchi R. Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes / R. Vuppalanchi, E. Teal, N. Chalasani // Am J Med Sci. – 2005. – Vol. 329. – P. 62–65. 
19. Browning J. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study / J. Browning // Hepatology. – 2006. – Vol. 44. – P. 466–471. 
20. Statins in liver disease: A molehill, an iceberg, or neither? / C. Argo, P. Loria, S.H. Caldwell, A. Lonardo // Hepatology. – 2008. - Vol. 48. – P. 662–669.
21. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis / N. Okoro, A. Patel, M. Goldstein [et al.] // Gastrointest Endosc. – 2008. – Vol. 68. – P. 69.